GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs, Inc. (NASDAQ:GOVXGet Rating) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 186,200 shares, a growth of 57.1% from the March 31st total of 118,500 shares. Based on an average daily volume of 849,400 shares, the short-interest ratio is presently 0.2 days.

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in shares of GeoVax Labs by 12.9% during the 3rd quarter. Geode Capital Management LLC now owns 59,097 shares of the company’s stock worth $255,000 after acquiring an additional 6,739 shares during the period. Two Sigma Securities LLC purchased a new position in shares of GeoVax Labs during the 3rd quarter worth about $49,000. Susquehanna International Group LLP purchased a new position in shares of GeoVax Labs during the 4th quarter worth about $42,000. Squarepoint Ops LLC purchased a new position in shares of GeoVax Labs during the 3rd quarter worth about $51,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of GeoVax Labs during the 4th quarter worth about $100,000. Institutional investors and hedge funds own 7.19% of the company’s stock.

Shares of GeoVax Labs stock traded down $0.03 during mid-day trading on Friday, hitting $0.79. 855,656 shares of the stock were exchanged, compared to its average volume of 2,145,668. GeoVax Labs has a twelve month low of $0.73 and a twelve month high of $7.50. The stock has a market capitalization of $5.60 million, a price-to-earnings ratio of -0.25 and a beta of 1.88. The company has a 50-day simple moving average of $1.30 and a 200 day simple moving average of $2.69.

GeoVax Labs (NASDAQ:GOVXGet Rating) last announced its quarterly earnings data on Wednesday, April 27th. The company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.11). GeoVax Labs had a negative return on equity of 139.41% and a negative net margin of 5,443.98%.

GeoVax Labs Company Profile (Get Rating)

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.

See Also

Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.